- Home
- ASND
ASND
Ascendis Pharma A/S
as 04-23-2025 4:00pm EST
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
| Founded: | 2006 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 9.1B | IPO Year: | 2015 |
| Target Price: | $202.00 | AVG Volume (30 days): | 562.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $111.09 - $169.37 | Next Earning Date: | 05-05-2025 |
| Revenue: | $376,478,932 | Revenue Growth: | 36.34% |
| Revenue Growth (this year): | 61.43% | Revenue Growth (next year): | 73.07% |
Latest Ascendis Pharma A/S News
ASND Breaking Stock News: Dive into ASND Ticker-Specific Updates for Smart Investing
TipRanks
6 days ago
Reddit initiated, Target downgraded: Wall Street’s top analyst calls
Zacks
7 days ago
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
MT Newswires
8 days ago
RBC Initiates Ascendis Pharma at Outperform, Speculative Risk With $205 Price Target
Insider Monkey
9 days ago
Is Ascendis Pharma A/S (ASND) the Best Growth Stock to Buy According to Billionaires?
Simply Wall St.
9 days ago
High Growth Tech Stocks In US With Potential For Expansion
MT Newswires
23 days ago
Ascendis Pharma Files New Drug Application for Achondroplasia Medication
GlobeNewswire
23 days ago
Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia
Zacks
a month ago
Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?
Compare ASND vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ASND Ascendis Pharma A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.